Dr. Armando Sardi was one of the first surgical oncologists in the U.S. to perform the groundbreaking cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) combination 24 years ago.
Hyperthermic Intraperitoneal Chemotherapy
Excellence in Research
He remains a pioneer today, refining techniques to improve the treatment of peritoneal mesothelioma.
Sardi is the medical director of the Institute for Cancer Care at Mercy Medical Center in Baltimore, one of America’s leaders in the treatment of peritoneal surface malignancies.
He has earned his reputation with local and international acclaim, advancing the field of surgical oncology by a desire to help every patient he sees.
“Mesothelioma is a rare disease, which is why it is so frequently mismanaged,” Sardi said. “People don’t know how to deal with it, don’t know how to treat it. That’s a real problem still today, and people are being hurt by that.”
Sardi has spent considerable time training others, authoring more than 120 medical papers and traveling the world to spread his knowledge about treating abdominal cancers such as mesothelioma.
“Cytoreduction is not going in and removing a few tumors. Cytoreduction is going in and doing an extensive surgery,” he said. “Unfortunately, it still is being done the wrong way in a lot of places. Too many people are still being told there is nothing they can do, when there actually is something they can do.”
Sardi performs an estimated eight to 10 cytoreduction and HIPEC combinations each month for a various peritoneal malignancies.
“As a patient, you need to find someone who has been doing it well for many years and really understands it,” he said. “We can’t help everyone. Everyone is different, but we have patients who are 15 to 16 years out after surgery and doing well.”
Sardi is known for his ability to treat late-stage, complex cancers others refuse to treat. The tougher it is, the harder he works.
He also is known for his research and never-ending search for better therapies and cancer cures.
Sardi is active in The Tumor Board at Mercy, which meets regularly and includes oncologists, radiologists, surgeons and nurses to collaborate and discuss cases. He is co-chair of Mercy’s Cancer Committee.
He has drawn international praise not only for advancing oncology worldwide, but for his humanitarian efforts to bring health care to underserved populations in developing nations.
Sardi was named to the “100 Most Influential Expatriates” list in Colombia, where his nonprofit, Partners for Cancer Care and Prevention, has helped thousands.
He also is the driving force behind Mercy’s annual National Cancer Day Survivor celebration and the Heat It To Beat It fundraising event named after the HIPEC procedure, which involves a high dose of heated chemotherapy.
Sardi received his medical degree from Universidad del Valle, in Cali, Colombia. He served his surgical residency at St. Agnes Hospital in Baltimore and completed fellowship training in surgical oncology at Ohio State University Hospital.
“I had a patient today who came all the way from California to see me, and I asked her why? She said, ‘Because you are a legend,’” Sardi said. “I never thought of myself like that. But I have been doing this for quite a while.”
Disclaimer: Dr. Armando Sardi has no professional affiliation with Asbestos.com.
Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers. Read More